Lantern Pharma Inc. (LTRN): Price and Financial Metrics


Lantern Pharma Inc. (LTRN): $5.24

0.34 (+6.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LTRN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LTRN Stock Price Chart Interactive Chart >

Price chart for LTRN

LTRN Price/Volume Stats

Current price $5.24 52-week high $11.39
Prev. close $4.90 52-week low $4.56
Day low $5.04 Volume 30,591
Day high $5.39 Avg. volume 36,482
50-day MA $5.30 Dividend yield N/A
200-day MA $6.04 Market Cap 56.75M

Lantern Pharma Inc. (LTRN) Company Bio


Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-11, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.


LTRN Latest News Stream


Event/Time News Detail
Loading, please wait...

LTRN Latest Social Stream


Loading social stream, please wait...

View Full LTRN Social Stream

Latest LTRN News From Around the Web

Below are the latest news stories about LANTERN PHARMA INC that investors may wish to consider to help them evaluate LTRN as an investment opportunity.

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting

DALLAS, September 23, 2022--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present preclinical data on the potency of Lantern’s drug candidate LP-284 for mantle cell lymphoma (MCL) and several other non-Hodgkin’s lymphomas at the Society of Hematologic

Yahoo | September 23, 2022

Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.

DALLAS, September 19, 2022--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on Sept. 22, 2022 at 12:00 p.m. ET. The webinar will focus on challenges in drug development for pediatric cancers and the potenti

Yahoo | September 19, 2022

Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate

Lantern Pharma Inc (NASDAQ: LTRN) will present preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research Special Conference. LP-184 is a small molecule drug candidate and next-generation acylfulvene that preferentially damages DNA in cancer cells harboring mutations in DNA damage repair (DDR) genes and overexpressing the enzyme PTGR1. Pancreatic cancer cells are expected to be sensitive to LP-184 treatment, as arou

Yahoo | September 14, 2022

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer

DALLAS, September 14, 2022--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present positive preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research (AACR) Special Confer

Yahoo | September 14, 2022

Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwright’s 24th Annual Global Investment Conference in September 2022

DALLAS, August 30, 2022--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company’s CEO & President, Panna Sharma, will be speaking at H.C. Wainwright’s 24th Annual Global Investment Conference, which is being held September 12-14, 2022 in New York, NY.

Yahoo | August 30, 2022

Read More 'LTRN' Stories Here

LTRN Price Returns

1-mo 4.80%
3-mo -9.50%
6-mo -25.25%
1-year -44.78%
3-year N/A
5-year N/A
YTD -34.34%
2021 -58.55%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6609 seconds.